Bhavneet Bhinder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bhavneet Bhinder has a total of 234 co-authors. Here are the top co-authors by number of shared publications:
- Olivier Elemento
Cornell Joan Klein Jacobs Center for Precision Nutrition and Health, Cornell University, Ithaca, USA
111 shared publications - Manik Uppal
Lymphoma Service, Division of Hematological Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
81 shared publications - Kenneth Wha Eng
Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, New York
80 shared publications - Andrea Sboner
Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA
62 shared publications - Juan Miguel Mosquera
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, USA
50 shared publications - Michael Sigouros
Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA
50 shared publications
Latest Publications
- Open Access
- 10 September 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase
Table S1 shows Overlap of differential regulated genes in EZH2high vs EZH2low and EZH2i vs vehicle of EZH2high cells comparisons identifies 12 common genes.
- 10 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase
Table S1 shows Overlap of differential regulated genes in EZH2high vs EZH2low and EZH2i vs vehicle of EZH2high cells comparisons identifies 12 common genes.
- Open Access
- 10 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-S10 from Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase
Supplementary Figure S1 shows correlation of EZH2 gene expression with FGA in METABRIC and TCGA breast cancer cohort suggests a link between EZH2 and CIN. Supplementary Figure S2 shows correlation between fraction genome altered (FGA) and EZH2 gene expression in TCGA LUAD cohort. Supplementary Figure S3 shows increased CIN in various TNBC, non-TNBC and and RPE1 cells and impact of EZH2 inhibition. Supplementary Figure S4 shows EZH2 inhibition and cell cycle analysis. Supplementary Figure S5 shows CUT & RUN seq and RNA-seq analysis. Supplementary Figure S6 shows visualization and experimental validation of EZH2 target genes. Supplementary Figure S7 shows EZH2 mediated TNKS regulates CIN. Supplementary Figure S8 shows multipolar mitosis and supernumerary centrosome analysis of the TNKS KO cells. Supplementary Figure S9 shows correlation of EZH2, CPAP and aneuploidy and effect of EZH2 inhibition on CPAP expression and cell cycle analysis of TNKSWT and TNKSKO LM2 cells. Supplementary Figure S10 shows impact of CIN modulation on proliferation and metastatic progression in EZH2 WT and EZH2 KO cells.
- 10 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-S10 from Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase
Supplementary Figure S1 shows correlation of EZH2 gene expression with FGA in METABRIC and TCGA breast cancer cohort suggests a link between EZH2 and CIN. Supplementary Figure S2 shows correlation between fraction genome altered (FGA) and EZH2 gene expression in TCGA LUAD cohort. Supplementary Figure S3 shows increased CIN in various TNBC, non-TNBC and and RPE1 cells and impact of EZH2 inhibition. Supplementary Figure S4 shows EZH2 inhibition and cell cycle analysis. Supplementary Figure S5 shows CUT & RUN seq and RNA-seq analysis. Supplementary Figure S6 shows visualization and experimental validation of EZH2 target genes. Supplementary Figure S7 shows EZH2 mediated TNKS regulates CIN. Supplementary Figure S8 shows multipolar mitosis and supernumerary centrosome analysis of the TNKS KO cells. Supplementary Figure S9 shows correlation of EZH2, CPAP and aneuploidy and effect of EZH2 inhibition on CPAP expression and cell cycle analysis of TNKSWT and TNKSKO LM2 cells. Supplementary Figure S10 shows impact of CIN modulation on proliferation and metastatic progression in EZH2 WT and EZH2 KO cells.
- Open Access
- 10 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Materials 1 from Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase
Supplementary materials include materials and methods, supplementary Figure S1 to S10, figure legends and references.
- 10 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials 1 from Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase
Supplementary materials include materials and methods, supplementary Figure S1 to S10, figure legends and references.
- Open Access
- 26 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (26) , eadz3351
Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities
We developed a pan-cancer patient-derived organoid (PDO) platform comprising 220 PDOs from 191 patients across 15 cancer types to advance functional precision oncology. Comprehensive characterization demonstrated high fidelity to parent tumors, with 93% histopathology concordance, 80% median genomic concordance for driver mutations, and a 0.85 median gene expression correlation. Expression profiles remained largely stable over 10 passages, ensuring reproducibility for long-term screening. Clonality analysis showed that 85% of dominant tumor clones were preserved, with genomic concordance directly reflecting clonal similarity. Even PDOs with lower concordance retained key oncogenic drivers, validating their utility as disease models. Functional assays revealed that 58% of PDOs from patients ineligible for US Food and Drug Administration–approved poly(adenosine 5′-diphosphate–ribose) polymerase inhibitors were sensitive to talazoparib, linked to DNA damage repair alterations. Furthermore, combination screens identified agents that overcome resistance, particularly in TP53 -mutant models. Our platform enables the investigation of targeted therapies and molecular drivers of drug sensitivity, providing translational insights for personalized treatment beyond current biomarker guidelines.
- 26 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (26) , eadz3351
Open AccessPatient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities
We developed a pan-cancer patient-derived organoid (PDO) platform comprising 220 PDOs from 191 patients across 15 cancer types to advance functional precision oncology. Comprehensive characterization demonstrated high fidelity to parent tumors, with 93% histopathology concordance, 80% median genomic concordance for driver mutations, and a 0.85 median gene expression correlation. Expression profiles remained largely stable over 10 passages, ensuring reproducibility for long-term screening. Clonality analysis showed that 85% of dominant tumor clones were preserved, with genomic concordance directly reflecting clonal similarity. Even PDOs with lower concordance retained key oncogenic drivers, validating their utility as disease models. Functional assays revealed that 58% of PDOs from patients ineligible for US Food and Drug Administration–approved poly(adenosine 5′-diphosphate–ribose) polymerase inhibitors were sensitive to talazoparib, linked to DNA damage repair alterations. Furthermore, combination screens identified agents that overcome resistance, particularly in TP53 -mutant models. Our platform enables the investigation of targeted therapies and molecular drivers of drug sensitivity, providing translational insights for personalized treatment beyond current biomarker guidelines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data Table 2 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Supplementary datatable 2 with analysis by clinical characteristics
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Table 2 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Supplementary datatable 2 with analysis by clinical characteristics
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Figure S4. Variant allele frequency in KS tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Figure S4. Variant allele frequency in KS tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Figure S3. Recurrent gains and losses.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Figure S3. Recurrent gains and losses.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data Table 1 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Supplementary data table 1 with mutation report
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Table 1 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Supplementary data table 1 with mutation report
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Figure S1. Analysis of KS exome sequencing.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Figure S1. Analysis of KS exome sequencing.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Figure S2. Mutations in KS exome tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Figure S2. Mutations in KS exome tumors.